© 2017 Genentech USA, Inc. All rights reserved. PDL/090216/0236( 1) Printed in USA.
Before you receive TECENTRIQ, tell
your healthcare provider about all your
medical conditions, including if you:
• Have immune system problems (such
as Crohn’s disease, ulcerative colitis, or
lupus); have had an organ transplant; have
lung or breathing problems; have liver
problems; have a condition that affects
your nervous system (such as myasthenia
gravis or Guillain-Barré syndrome); or are
being treated for an infection
• Are pregnant or plan to become pregnant
– TECENTRIQ can harm your unborn baby
– If you are able to become pregnant,
you should use an effective method
of birth control during your treatment
and for at least 5 months after the last
dose of TECENTRIQ
• Are breastfeeding or plan to breastfeed
– It is not known if TECENTRIQ passes into
your breast milk
– Do not breastfeed during treatment and
for at least 5 months after the last dose
Tell your healthcare provider about all the
medicines you take, including prescription
and over-the-counter medicines, vitamins,
and herbal supplements.
The most common side effects of
TECENTRIQ in people with non-small cell
lung cancer include:
• Feeling tired
• Decreased appetite
• Shortness of breath
• Muscle or bone pain
TECENTRIQ may cause fertility problems in
females, which may affect the ability to have
children. Talk to your healthcare provider if
you have concerns about fertility.
These are not all the possible side effects of
TECENTRIQ. Ask your healthcare provider or
pharmacist for more information.
You may report side effects to the FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to
Genentech at 1-888-835-2555.
Please see Summary of Medication Guide
on the following page.
A path forward
† A 60-minute initial infusion and, if tolerated, a 30-minute treatment every 3 weeks.
‡ Your healthcare provider will give you TECENTRIQ into your vein through an intravenous (IV) line over 30-60 minutes.
1. TECENTRIQ Prescribing Information. Genentech, Inc. April 2017.
Ask your doctor about TECENTRIQ, given once every 3 weeks† as an intravenous infusion‡.